about
Activation of innate immunity accelerates sialoadenitis in a mouse model for Sjögren's syndrome-like disease.Saliva as a diagnostic fluid.Mesenchymal stromal cells improve salivary function and reduce lymphocytic infiltrates in mice with Sjögren's-like diseaseCytokines in Sjogren's syndrome: potential therapeutic targets.Dysfunction of lacrimal and salivary glands in Sjögren's syndrome: nonimmunologic injury in preinflammatory phase and mouse model.Expression of IL-17, IL-23 and their receptors in minor salivary glands of patients with primary Sjögren's syndromeSignificance of Interleukin-6/STAT Pathway for the Gene Expression of REG Iα, a New Autoantigen in Sjögren's Syndrome Patients, in Salivary Duct Epithelial Cells.Temporal changes in salivary glands of non-obese diabetic mice as a model for Sjögren's syndrome.P2X7 receptor activation induces inflammatory responses in salivary gland epithelium.Topical administration of Esculetin as a potential therapy for experimental dry eye syndrome.Aquaporin gene therapy corrects Sjögren's syndrome phenotype in miceThe T cell in Sjogren's syndrome: force majeure, not spectateur.Sjögren's syndrome in older patients: aetiology, diagnosis and management.Inflammation-related cytokines in oral lichen planus: an overview.B-cell hyperactivity in primary Sjögren's syndrome.Present and future of biologic drugs in primary Sjögren's syndrome.Clinical relevance of RORγ positive and negative subsets of CD161+CD4+ T cells in primary Sjögren's syndrome.Innate immunity in Sjögren's syndrome.Exocrine Gland Morphogenesis: Insights into the Role of Amphiregulin from Development to Disease.Cortical bone density and thickness alterations by high-resolution peripheral quantitative computed tomography: association with vertebral fractures in primary Sjögren's syndrome.Metabolic syndrome in Sjögren's syndrome patients: a relevant concern for clinical monitoring.Interferon-γ treatment in vitro elicits some of the changes in cathepsin S and antigen presentation characteristic of lacrimal glands and corneas from the NOD mouse model of Sjögren's Syndrome.Involvement of toll-like receptors in autoimmune sialoadenitis of the non-obese diabetic mouse.Interleukin-6 deficiency corrects nephritis, lymphocyte abnormalities, and secondary Sjögren's syndrome features in lupus-prone Sle1.Yaa mice.Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjogren's syndrome.Interleukin-6/STAT pathway is responsible for the induction of gene expression of REG Iα, a new auto-antigen in Sjögren׳s syndrome patients, in salivary duct epithelial cells.Serum components and clinical efficacies of autologous serum eye drops in dry eye patients with active and inactive Sjogren syndrome.Effects of periodontal treatment on primary sjȫgren's syndrome symptoms.Cardamonin inhibits pro-inflammatory cytokine production and suppresses NO pathway in PBMCs from patients with primary Sjögren's syndrome.Capsaicin regulates the NF-κB pathway in salivary gland inflammation.Association between the clinical severity of oral lichen planus and anti-TPO level in thyroid patients.Elevated IL-37, IL-18 and IL-18BP serum concentrations in patients with primary Sjögren's syndrome.
P2860
Q30424360-D9275EA0-1280-4957-8917-0D9903BFB7D3Q33752749-EEE4E51E-0931-461D-92A9-C1D96A6343A6Q34299698-B2BCCDF3-A25F-43B2-BC5E-D5FAA7799AE1Q34601660-710DD3DA-5206-45BE-B4B5-509F9DCD7D5BQ35031736-CC71FE24-0E83-4CAD-B28D-AF24522BB282Q35676007-64CB834A-8C84-469D-BA3B-AB6559C947F8Q36060629-E7908790-A1D3-40B8-9D2B-52F4404F73CDQ36214855-B9770EA3-0E19-4FAA-B43D-675A468008A3Q36312386-0A29FFA5-1A96-4B32-A3CD-0591773AEF7CQ36413214-997A4146-5D5B-4D4E-B4E1-1A121ABF7938Q36931123-474CACCE-7DBF-4FFC-B335-5B6561E8A28EQ38019664-DC47F8DE-2C0D-41C0-A50C-2F9ADE568289Q38076070-F6004400-149A-4635-AFE1-9C192B5EC891Q38170492-5CB74118-42FF-4E86-94CE-0C83941A4F4FQ38190590-F178E935-F9FD-4AB4-8362-FF9847F0A98AQ38822415-FDE2B586-3DEC-424E-830B-EC0546F76FF7Q39226046-1A6E3F1D-9312-4DEA-A77D-01BA0955ACB6Q39232871-6F249099-3439-4956-809B-EB43B1A38E9FQ39358786-FD3E72B2-98B7-4F8A-80AF-41685B92E7B3Q39368304-16B0EA78-FB0B-4033-B146-489A77C82989Q40540065-E65A03CB-E35E-433D-BE34-646CF70B7E7AQ41140614-2F122F1D-EF60-4169-8228-DFDC9C272663Q41930154-05A74B73-2003-46B3-BF58-228E2C26A6DCQ42845944-DEFE6B3A-8052-42FA-B957-9829A09B4FB2Q45754988-C4B6671F-E111-484D-9720-9D49F4A2BED0Q46974371-1BADDD16-547B-42A4-862B-DDD031084D59Q47203561-10D0DB72-76F2-40A5-AAC7-2A000A247C6BQ47886685-18A76A04-7C04-44EB-8B82-BB2EF61ABE52Q50180338-86AD9F58-63CC-4AC5-9CD8-404938774ECDQ51057189-62055C18-13B3-43F8-98FE-067694B1615CQ51200070-F5B8DCA8-9FCE-45B5-9A4A-A27AFDACABDCQ51213911-59212CAB-9DDB-433A-85E9-EDE1AF575D95
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cytokines in Sjögren's syndrome.
@en
Cytokines in Sjögren's syndrome.
@nl
type
label
Cytokines in Sjögren's syndrome.
@en
Cytokines in Sjögren's syndrome.
@nl
prefLabel
Cytokines in Sjögren's syndrome.
@en
Cytokines in Sjögren's syndrome.
@nl
P2093
P2860
P1433
P1476
Cytokines in Sjögren's syndrome.
@en
P2093
P2860
P304
P356
10.1111/J.1601-0825.2009.01582.X
P577
2009-06-10T00:00:00Z